SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MorphoSys AG (MOR)
An SI Board Since January 2000
Posts SubjectMarks Bans
421 15 0
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
32120101210 MorphoSys Signs Long-Term Alliance with Pfizer on Sloning Technology PlGermanecki-12/22/2010
32020101210 MorphoSys Announces Three New Clinical Milestones.December 10, 2010 / 7Germanecki-12/22/2010
31920101202 MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in ChGermanecki-12/22/2010
31820101125 MorphoSys Presents Comprehensive Pipeline and Technology Update at R&amGermanecki-12/22/2010
31720101104 AbD Serotec Secures Exclusive Worldwide License to Research Antibody frGermanecki-12/22/2010
31620101029 MorphoSys AG Reports Nine Months 2010 Results.October 29, 2010 / 8:00 aGermanecki-12/22/2010
31520101019: MorphoSys Opts for Second Pre-Development Program within Strategic AntGermanecki-10/19/2010
31420101014: AbD Serotec Selected as Preferred Supplier for Custom Monoclonal AntibGermanecki-10/19/2010
31320101012: MorphoSys and Proteros Biostructures Receive Research Grant to DevelopGermanecki-10/19/2010
31220101007: MorphoSys Announces Acquisition of Sloning. October 07, 2010 / 05:01 Germanecki-10/19/2010
31120101005: MorphoSys Further Strengthens US Patent Position on Core Technologies.Germanecki-10/19/2010
31020100916: AbD Serotec Secures Exclusive Worldwide Manufacturing License to Key RGermanecki-10/19/2010
309MorphoSys Initiates Program Against Drug-Resistant MRSA Infections September 02,Germanecki-9/2/2010
308MorphoSys to Present at Three Investor Conferences in September September 01, 20Germanecki-9/2/2010
307MorphoSys to Present at Three Investor Conferences in September 16:08 01.09.10 Germanecki-9/1/2010
306MorphoSys Announces Clinical Milestone from Strategic Alliance August 02, 2010 Germanecki-8/4/2010
305MorphoSys AG Reports Six Months 2010 Results July 28, 2010 / 07:00 Full Year GGermanecki-8/4/2010
304AbD Serotec Secures Exclusive Worldwide License to Key Diagnostic Antibody JulyGermanecki-8/4/2010
303MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202 andGermanecki-8/4/2010
302MorphoSys Announces Clinical Milestone from Strategic Alliance July 01, 2010 / Germanecki-7/2/2010
301MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical AntibGermanecki-7/2/2010
300MorphoSys Announces Clinical Milestone June 22, 2010 / 08:30 <b>First ofGermanecki-6/24/2010
299AbD Serotec Enters New Growth Area Print . AbD Serotec Enters New Growth Area.MGermanecki-5/21/2010
298MorphoSys AG Reports Results for the First Quarter of 2010 April 27, 2010 / 08:Germanecki-5/1/2010
297MorphoSys Granted Further Patent on its Core Antibody Technology in Japan MARTINGermanecki-3/15/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News